Literature DB >> 1390844

Dextran sulfate inhibits fusion of influenza virus and cells expressing influenza hemagglutinin with red blood cells.

M Krumbiegel1, D S Dimitrov, A Puri, R Blumenthal.   

Abstract

The influence of dextran sulfate with molecular weights of 500,000 and 8000 on binding and fusion of influenza virus (X31 strain) and of cells expressing influenza hemagglutinin (GP4F) with red blood cells (RBC) was investigated by spectrofluorimetry using virus and RBC labeled with the fluorescent dye octadecyl rhodamine B (R18). There was no significant inhibition of binding of virus and GP4F cells to red blood cells by dextran sulfate, but the polymer strongly inhibited the low pH induced fusion. Virus-RBC fusion was completely blocked by the high molecular weight dextran sulfate at concentrations as low as 0.5 mg/ml. Inhibition of RBC-GP4F cell fusion by dextran sulfate in the same concentration range was not as pronounced but the effect was potentiated by Ca2+. The polymer was only inhibitory when added at early steps of the fusion reaction, but the pH-induced conformational change of the hemagglutinin was not affected by dextran sulfate as measured by its susceptibility to proteolytic digestion. Removal of dextran sulfate after low pH-requiring steps allowed the system to fuse at neutral pH indicating that the inhibitory effect requires the continuous presence of dextran sulfate during the fusion reaction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1390844     DOI: 10.1016/0005-2736(92)90353-n

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  Dextran sulfate can act as an artificial receptor to mediate a type-specific herpes simplex virus infection via glycoprotein B.

Authors:  A P Dyer; B W Banfield; D Martindale; D M Spannier; F Tufaro
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

Review 2.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 3.  Progress of small molecular inhibitors in the development of anti-influenza virus agents.

Authors:  Xiaoai Wu; Xiuli Wu; Qizheng Sun; Chunhui Zhang; Shengyong Yang; Lin Li; Zhiyun Jia
Journal:  Theranostics       Date:  2017-02-08       Impact factor: 11.556

Review 4.  Emerging antiviral strategies to interfere with influenza virus entry.

Authors:  Evelien Vanderlinden; Lieve Naesens
Journal:  Med Res Rev       Date:  2013-06-25       Impact factor: 12.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.